Onartuzumab is a humanized monoclonal antibody designed for the treatment of advanced non-small-cell lung cancer. [1] [2] [3] Onartuzumab was developed by Genentech, Inc. It is …

Here, we describe the development of a one-armed (monovalent) antibody, onartuzumab, targeting the receptor tyrosine kinase MET. While initial screening of bivalent antibodies …

2013年8月6日 · To address this limitation, we have developed onartuzumab, an Escherichia coli-derived, humanized, and affinity-matured monovalent monoclonal antibody against MET, …

Purpose The phase III OAM4971g study (METLung) examined the efficacy and safety of onartuzumab plus erlotinib in patients with locally advanced or metastatic non-small-cell lung …

Onartuzumab, a recombinant humanized monovalent monoclonal antibody directed against MET, the receptor for the hepatocyte growth factor, has been investigated for the treatment of solid …

2016年12月12日 · Here we report the efficacy and safety results of the phase III METLung trial (OAM4971g) comparing onartuzumab plus erlotinib with placebo plus erlotinib for patients with …

2014年3月13日 · Purpose: This first-in-human study evaluated the safety, immunogenicity, pharmacokinetics, and antitumor activity of onartuzumab, a monovalent antibody against the …

Onartuzumab (MetMAb) is a chimeric, humanized, monovalent monoclonal antibody directed against Met that inhibits the binding of HGF to the Met ligand binding site (Martens et al., …

2016年4月5日 · Onartuzumab is a monovalent monoclonal antibody that binds with the extracellular domain of the MET receptor. Given the role of MET in non–small-cell lung cancer …

itation, we have developed onartuzumab, an Escherichia coli-derived, humanized, and affinity-matured monovalent monoclo-nal antibody against MET, generated using the knob-into-hole …